Home > Publications database > Can benign lymphoid tissue changes in 18F-FDG PET/CT predict response to immunotherapy in metastatic melanoma?315 > print

001     141819
005     20240229112527.0
024 7 _ |a 10.1007/s00262-018-2279-9
|2 doi
024 7 _ |a pmid:30478475
|2 pmid
024 7 _ |a 0340-7004
|2 ISSN
024 7 _ |a 1432-0851
|2 ISSN
024 7 _ |a =
|2 ISSN
024 7 _ |a Cancer
|2 ISSN
024 7 _ |a immunology,
|2 ISSN
024 7 _ |a immunotherapy
|2 ISSN
024 7 _ |a (Internet)
|2 ISSN
037 _ _ |a DKFZ-2018-02087
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Sachpekidis, Christos
|0 P:(DE-He78)69d2d5247c019c2a2075502dc11bf0b2
|b 0
|e First author
|u dkfz
245 _ _ |a Can benign lymphoid tissue changes in 18F-FDG PET/CT predict response to immunotherapy in metastatic melanoma?315
260 _ _ |a Heidelberg
|c 2019
|b Springer
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1558077500_10927
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a An association between immune-related adverse events (irAEs) caused by immunotherapeutic agents and the clinical benefit of immunotherapy has been suggested. We retrospectively evaluated by means of 18F-FDG PET/CT lymphoid tissue changes in the mediastinal/hilar lymph nodes and the spleen in response to ipilimumab administration in metastatic melanoma.A total of 41 patients with unresectable metastatic melanoma underwent 18F-FDG PET/CT before the start of ipilimumab (baseline PET/CT), after two cycles (interim PET/CT) and at the end of treatment (late PET/CT). Data analysis was focused on the mediastinal/hilar lymph nodes and the spleen. The patients' best clinical response (BCR) was used as reference.According to the BCR reference, 31 patients showed disease control (DC) and 10 patients showed progressive disease (PD). Mediastinal/hilar lymph node evaluation revealed that in total 4 patients in the interim or late PET/CT (10%) demonstrated a 'sarcoid-like lymphadenopathy' as response to treatment (LN-positive). All LN-positive patients responded to ipilimumab with DC. On the other hand, no significant differences between the DC and PD groups regarding both semi-quantitative and quantitative 18F-FDG PET spleen-related parameters at baseline and as response to treatment were detected.Based on our findings, 10% patients in the interim or late PET/CT showed 'sarcoid-like lymphadenopathy' as response to treatment. All these patients showed disease control, implying a relation between the appearance of sarcoid-like lymphadenopathy and the clinical benefit of anti-CTLA-4 therapy. On the other hand, quantitative 18F-FDG PET analysis of the spleen showed a poor performance in predicting clinical benefit to ipilimumab.
536 _ _ |a 315 - Imaging and radiooncology (POF3-315)
|0 G:(DE-HGF)POF3-315
|c POF3-315
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Larribère, Lionel
|0 P:(DE-He78)f89c856740c99008f4fbc1efa501d4f9
|b 1
|u dkfz
700 1 _ |a Kopp-Schneider, Annette
|0 P:(DE-He78)bb6a7a70f976eb8df1769944bf913596
|b 2
|u dkfz
700 1 _ |a Hassel, Jessica C
|0 P:(DE-HGF)0
|b 3
700 1 _ |a Dimitrakopoulou-Strauss, Antonia
|0 P:(DE-He78)b2df3652dfa3e19d5e96dfc53f44a992
|b 4
|e Last author
|u dkfz
773 _ _ |a 10.1007/s00262-018-2279-9
|0 PERI:(DE-600)1458489-x
|n 2
|p 297-303
|t Cancer immunology immunotherapy
|v 68
|y 2019
|x 1432-0851
909 C O |p VDB
|o oai:inrepo02.dkfz.de:141819
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)69d2d5247c019c2a2075502dc11bf0b2
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)f89c856740c99008f4fbc1efa501d4f9
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-He78)bb6a7a70f976eb8df1769944bf913596
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 P:(DE-He78)b2df3652dfa3e19d5e96dfc53f44a992
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-315
|2 G:(DE-HGF)POF3-300
|v Imaging and radiooncology
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2019
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b CANCER IMMUNOL IMMUN : 2017
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
920 1 _ |0 I:(DE-He78)E060-20160331
|k E060
|l KKE Nuklearmedizin
|x 0
920 1 _ |0 I:(DE-He78)A370-20160331
|k A370
|l KKE Dermatoonkologie
|x 1
920 1 _ |0 I:(DE-He78)C060-20160331
|k C060
|l Biostatistik
|x 2
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)E060-20160331
980 _ _ |a I:(DE-He78)A370-20160331
980 _ _ |a I:(DE-He78)C060-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21